Continuous Glucose Monitoring (CGM) Market Size, Share & Trends Analysis Report By Product (Transmitters & Receivers, Sensors, Insulin Pumps), By Applications (Hospital, Homecare), By End Use, By Region, and Segment Forecasts - 2035

Continuous Glucose Monitoring (CGM) Market Overview

The global continuous glucose monitoring (cgm) market size was valued at USD 1541.13 million in 2025 and is projected to grow from USD 1641.15 million in 2026 to USD 1981.87 million by 2035, at a CAGR of 6.49%.

The Continuous Glucose Monitoring (CGM) Market is expanding steadily as diabetes management shifts toward real-time glucose visibility, personalized treatment, connected monitoring, automated insulin delivery, and greater use of devices outside traditional clinical settings. Sensors are estimated to account for approximately 51% of current product demand because they represent the recurring component of most CGM systems and are typically replaced after approximately 10 to 15 days depending on device design. Transmitters & Receivers account for around 29%, while Insulin Pumps represent approximately 20%, producing a complete 100% product distribution. Homecare dominates application demand with approximately 76% share, while Hospital accounts for 24%, reflecting the increasing importance of self-management and remote data access. Modern CGM systems can generate glucose readings every 1 to 5 minutes and produce more than 250 measurements per day, offering substantially greater visibility than intermittent finger-stick testing. Through 2035, the market's 6.49% CAGR is expected to be supported by longer sensor wear, smartphone connectivity, predictive alerts, automated insulin delivery, remote monitoring, compact device design, and increasing adoption among insulin-treated users.

The United States represents one of the most important national markets for continuous glucose monitoring because of high technology adoption, established diabetes-care infrastructure, growing use of connected health devices, and strong availability of sensor-based glucose monitoring. North America is estimated to account for approximately 43% of current global market demand, with the U.S. contributing the majority of regional consumption. Medtronic, Abbott, Senseonics, and Dexcom provide 4 supplied-company representations from the U.S. Homecare is estimated to account for approximately 78% of U.S. CGM utilization because users increasingly review glucose values through smartphones, dedicated receivers, and connected insulin-delivery platforms outside hospitals. Modern systems can provide more than 280 glucose readings during a 24-hour period when measurements are refreshed every 5 minutes, while alarms can alert users to rapidly changing glucose trends before scheduled manual checks would normally occur. Through 2035, U.S. demand is expected to remain supported by broader outpatient adoption, automated insulin delivery, extended sensor wear, connected care, and greater emphasis on time-in-range management.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: Sensors are expected to remain the leading supplied product category with approximately 51% market share, supported by recurring replacement demand and sensor wear periods commonly spanning approximately 10 to 15 days.
• Leading Application: Homecare is projected to account for approximately 76% of current demand as users increasingly manage glucose data through smartphones, receivers, remote platforms, and connected insulin-delivery systems.
• Leading Region: North America is estimated to account for approximately 43% of current market activity, supported by strong connected-care adoption, advanced diabetes management, and widespread use of sensor-based monitoring.
• Fastest Growing Region: Asia-Pacific currently represents approximately 25% of global demand and offers faster expansion potential through rising diabetes awareness, improving device access, digital health adoption, and larger treated populations.
• Technology Trend: Longer-duration sensing is becoming increasingly important, with advanced CGM platforms extending continuous wear beyond 10 days while reducing the frequency of sensor replacement and insertion.
• Market Driver: Real-time glucose visibility remains a major demand driver because modern systems can generate more than 250 measurements every 24 hours, enabling users to recognize trends and respond earlier.
• Competitive Landscape: Competition spans 9 supplied companies, intensifying development around sensor miniaturization, smartphone connectivity, predictive alerts, automated insulin delivery, longer wear duration, and remote monitoring capabilities.
• Future Outlook: Insulin Pumps currently account for approximately 20% of product demand and are expected to gain strategic importance through tighter integration with CGM data and automated insulin-delivery algorithms.

Latest Trends

Longer sensor wear, smaller form factors, factory calibration, and more seamless smartphone integration are among the most important trends shaping the Continuous Glucose Monitoring (CGM) Market. Sensors currently account for approximately 51% of product demand and remain the center of innovation because recurring replacement creates strong incentives to improve comfort, longevity, insertion simplicity, and data reliability. Many contemporary CGM systems provide readings every 1 to 5 minutes, generating between approximately 288 and more than 1,000 data points per day depending on sampling architecture. Extending wear from around 10 days toward 15 days can reduce the number of annual sensor replacements by more than 10 units for a continuously monitored user. Homecare, which represents approximately 76% of application demand, benefits particularly from these advances because fewer insertions and simplified setup can improve day-to-day convenience. Through 2035, product development is expected to emphasize extended wear, lower-profile sensors, simplified applicators, reduced calibration requirements, and more automated data interpretation.

Integration of CGM with insulin delivery and digital decision support is also accelerating as the market moves from passive glucose measurement toward connected therapeutic ecosystems. Insulin Pumps represent approximately 20% of current product demand and increasingly interact with CGM data to adjust insulin delivery according to glucose direction, predicted lows, and target ranges. Advanced algorithms can evaluate a new glucose reading every 5 minutes and make hundreds of dosing-related calculations during a 24-hour period. Transmitters & Receivers, accounting for approximately 29% of product demand, are also becoming more software-centric as smartphones and cloud platforms assume a greater role in data visualization and remote sharing. Hospital applications at approximately 24% share benefit from access to continuous trend data, while Homecare remains dominant because monitoring occurs throughout daily life. Through 2035, CGM systems are expected to increasingly combine predictive analytics, remote clinician access, insulin-pump connectivity, personalized alerts, and automated treatment support.

Market Dynamics

Driver

""Real-time glucose visibility is accelerating adoption across everyday diabetes management.""

The principal driver of the Continuous Glucose Monitoring (CGM) Market is the shift from intermittent glucose checks toward continuous, trend-based management that gives users and clinicians a more complete picture of glucose behavior throughout the day and night. Homecare currently accounts for approximately 76% of application demand because CGM enables users to monitor glucose during meals, exercise, sleep, work, and medication adjustments without relying exclusively on scheduled measurements. Sensors represent approximately 51% of product demand and can generate more than 250 readings in a 24-hour period, providing substantially greater data density than several manual checks per day. Trend arrows and alerts can help users recognize rapid glucose changes before levels move further outside target ranges. Transmitters & Receivers account for approximately 29% of product demand and increasingly support smartphone connectivity and remote data sharing. Insulin Pumps at approximately 20% share add another layer of functionality when CGM data is used in automated insulin-delivery systems. Through 2035, growing emphasis on time in range, predictive alerts, connected diabetes care, and reduced dependence on finger-stick testing is expected to sustain the market's 6.49% CAGR.

Restraint

""Device cost, sensor replacement, and access limitations can restrict wider adoption.""

A major restraint affecting the Continuous Glucose Monitoring (CGM) Market is the recurring cost and access burden associated with sensors, transmitters, receivers, and connected insulin-delivery equipment. Sensors account for approximately 51% of product demand and typically require replacement every 10 to 15 days, meaning a continuously monitored user may need more than 24 sensors per year depending on wear duration. Transmitters & Receivers represent approximately 29% of product demand and can add additional equipment, replacement, and connectivity requirements. Insulin Pumps at approximately 20% share involve even greater system complexity because pump therapy requires consumables, training, infusion-set management, and regular device maintenance. Homecare accounts for approximately 76% of application demand, but affordability can vary considerably across reimbursement structures and geographies. Device performance can also be affected by insertion-site issues, adhesive failure, signal interruptions, or physiological lag between interstitial and blood glucose. Through 2035, wider adoption will depend on longer sensor wear, lower manufacturing costs, simpler reimbursement, improved adhesive performance, and reduced dependence on multiple separate hardware components.

Opportunity

""Longer sensor wear and connected insulin delivery create significant expansion opportunities.""

Extended sensor duration, automated insulin delivery, remote monitoring, and broader outpatient use create substantial opportunities in the Continuous Glucose Monitoring (CGM) Market. Asia-Pacific currently accounts for approximately 25% of global demand and offers strong expansion potential as diabetes awareness increases, digital health infrastructure improves, and connected devices become more accessible across large populations. Sensors, representing approximately 51% of product demand, provide the largest opportunity because extending wear from 10 days to 15 days can reduce annual replacement frequency by approximately one-third. Insulin Pumps at approximately 20% share offer additional growth potential as CGM data becomes increasingly integrated with automated dosing algorithms that evaluate glucose trends every 5 minutes. Homecare, accounting for approximately 76% of application demand, creates a large addressable market for smartphone-connected systems capable of sharing data with caregivers and clinicians remotely. Through 2035, suppliers offering smaller sensors, longer wear, simpler insertion, predictive alerts, stronger connectivity, and tighter integration with insulin delivery are expected to capture increasing adoption.

Challenge

""Maintaining accuracy, comfort, connectivity, and user trust remains technically demanding.""

A major challenge for the Continuous Glucose Monitoring (CGM) Market is maintaining reliable glucose accuracy across different users, physiological conditions, sensor sites, wear durations, and daily activities while also keeping devices comfortable and simple. Sensors represent approximately 51% of product demand and may remain attached for 10 to 15 days, requiring adhesives that tolerate bathing, exercise, perspiration, sleep, and repeated clothing contact. CGM measures interstitial glucose rather than direct blood glucose, and rapid changes can create a short physiological lag that users must understand when making treatment decisions. Systems producing readings every 1 to 5 minutes generate more than 250 daily data points, making algorithm quality and alert management essential to avoid excessive alarms or confusing information. Homecare represents approximately 76% of application demand, meaning most device operation occurs without immediate clinical supervision. Transmitters & Receivers at approximately 29% share also depend on stable wireless communication and software compatibility. Through 2035, manufacturers will need to improve sensor accuracy, adhesive reliability, cybersecurity, battery performance, alert personalization, and user education while keeping devices compact and easy to operate.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

By Types

Transmitters & Receivers: Transmitters & Receivers account for approximately 29% of the current Continuous Glucose Monitoring (CGM) Market and remain an important product category because they support communication between sensors, display devices, smartphones, and connected diabetes-management platforms. These components increasingly use low-power wireless technologies to transfer glucose information every 1 to 5 minutes, helping users review trends without manually scanning each reading. Modern receivers can display more than 250 glucose values during a 24-hour period and typically present trend arrows, alerts, time-in-range summaries, and historical data. Homecare applications, which represent approximately 76% of total demand, provide the strongest usage environment because patients require simple, reliable interfaces throughout daily activity. Smartphone compatibility is gradually reducing dependence on dedicated receivers in some configurations, but dedicated hardware remains relevant where users need an independent display or where clinical workflows require standardized equipment. Through 2035, Transmitters & Receivers are expected to maintain approximately 29% share as manufacturers improve wireless reliability, battery life, compactness, cloud connectivity, and interoperability with insulin-delivery systems.

Sensors: Sensors represent approximately 51% of current market demand and remain the leading product type because they form the recurring, body-worn component responsible for continuous glucose measurement. Most modern sensors are designed for wear periods of approximately 10 to 15 days, although longer-duration systems are expanding in selected platforms. Extending wear from 10 days to 15 days can reduce annual replacement frequency from approximately 36 sensors to around 24 sensors for continuously monitored users, improving convenience and potentially reducing overall consumable burden. Sensors commonly measure interstitial glucose every 1 to 5 minutes and can therefore produce more than 250 readings per day. Homecare remains the primary application because users wear devices during sleep, exercise, work, meals, and daily routines. Sensor development increasingly focuses on smaller insertion devices, lower-profile housings, improved adhesives, reduced calibration, and stronger accuracy across the full wear period. Through 2035, Sensors are expected to retain approximately 51% market share as longer wear duration, easier insertion, smaller form factors, and broader outpatient adoption continue to support recurring demand.

Insulin Pumps: Insulin Pumps account for approximately 20% of the current Continuous Glucose Monitoring (CGM) Market and are increasingly important because of their integration with CGM data in automated insulin-delivery systems. These platforms can evaluate glucose values every 5 minutes and adjust insulin delivery according to current levels, trend direction, predictive algorithms, and user-defined targets. An integrated pump and CGM system can therefore make more than 280 automated calculations during a 24-hour period. Homecare applications dominate because most pump users rely on connected systems continuously outside hospital settings. The value of pump integration is particularly strong when CGM data is used to suspend insulin before predicted low glucose or to increase delivery when glucose is trending upward. Modern pumps are also becoming smaller, more software-driven, and more closely integrated with mobile applications. Through 2035, Insulin Pumps are expected to maintain approximately 20% share while gaining strategic importance through closed-loop systems, automated dosing, remote monitoring, and more personalized glucose-control algorithms.

By Applications

Hospital: Hospital applications account for approximately 24% of the current Continuous Glucose Monitoring (CGM) Market and remain important in specialist diabetes care, inpatient monitoring, treatment adjustment, education, and initiation of connected insulin-delivery systems. Hospitals can use CGM trend information to review more than 250 glucose measurements per day, providing clinicians with a more detailed picture of glucose variability than several intermittent checks. Continuous data can help identify overnight hypoglycemia, post-meal spikes, and patterns associated with medication changes. Hospital environments also play an important role in device training, sensor insertion, pump setup, and interpretation of time-in-range metrics. In selected cases, clinicians can review glucose records covering 7 to 14 days to identify recurring trends before adjusting therapy. Through 2035, Hospital applications are expected to retain approximately 24% share as CGM becomes more integrated into specialist diabetes pathways, inpatient monitoring protocols, and connected-care programs.

Homecare: Homecare represents approximately 76% of current market demand and remains the dominant application because CGM is designed primarily for continuous use during everyday life rather than only during clinical visits. Users can monitor glucose during meals, sleep, exercise, driving, work, and medication adjustments, allowing more timely responses to changing glucose levels. Modern systems commonly generate readings every 1 to 5 minutes and can produce more than 280 data points per day at a 5-minute interval. Smartphone connectivity allows users to review current glucose, trend arrows, alerts, and time-in-range information without carrying a separate receiver in some systems. Caregivers and clinicians may also review data remotely where sharing is enabled. Longer wear periods of approximately 10 to 15 days reduce insertion frequency and improve convenience. Through 2035, Homecare is expected to retain approximately 76% share as remote monitoring, automated insulin delivery, smartphone integration, and self-management continue to expand.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America currently accounts for approximately 43% of the global Continuous Glucose Monitoring (CGM) Market and remains the leading region because of high device adoption, advanced diabetes-care infrastructure, strong reimbursement penetration, and extensive use of connected digital-health platforms. The United States contributes the majority of regional demand and is represented within the supplied competitive landscape by Medtronic, Abbott, Senseonics, and Dexcom. Homecare remains the dominant application and aligns closely with the global estimate of approximately 76%, supported by widespread smartphone connectivity, remote data sharing, and automated insulin-delivery adoption. Sensors remain the leading product type with approximately 51% share because they are replaced every 10 to 15 days in many systems and therefore generate recurring demand. Modern devices can provide more than 280 readings per day, allowing users and clinicians to analyze glucose patterns in far greater detail than intermittent testing.

The region's approximately 43% share is further supported by growing use of insulin-pump integration, predictive alerts, extended-wear sensors, and cloud-based data platforms. Insulin Pumps account for approximately 20% of global product demand and are increasingly linked with CGM data in automated systems that evaluate glucose every 5 minutes. Dedicated Transmitters & Receivers, representing approximately 29% of product demand, remain relevant where users require independent hardware or standardized clinical interfaces. North American product development also emphasizes reduced sensor size, stronger adhesives, and longer wear periods. Through 2035, the region is expected to maintain leadership as outpatient adoption, automated insulin delivery, remote care, and digital diabetes management continue to expand.

Europe

Europe currently represents approximately 24% of the global Continuous Glucose Monitoring (CGM) Market and remains an important region because of established diabetes-care systems, public and private reimbursement structures, growing use of digital health, and increasing emphasis on reducing hypoglycemia and improving time in range. GlucoMenDay from Italy provides supplied-company representation within the region. Homecare remains the principal application and aligns with the global share of approximately 76% because CGM increasingly supports self-management outside hospitals. Sensors account for approximately 51% of global product demand and are central to regional adoption as users move toward longer wear, simplified insertion, and factory-calibrated systems. A device operating at 5-minute intervals can generate approximately 288 glucose values per day, creating a detailed record that can be reviewed during consultations and remote-care sessions.

Europe's approximately 24% share is also supported by strong interest in interoperability, remote monitoring, and connected insulin delivery. Hospital applications account for approximately 24% of global demand and remain important for device initiation, patient education, and treatment optimization. Clinical teams may review 14 days of CGM data to evaluate time in range, glucose variability, and repeated low or high patterns. Insulin Pumps at approximately 20% share also benefit as more systems incorporate automated adjustment based on CGM trends. Through 2035, Europe is expected to remain a significant market as sensor access broadens, digital diabetes programs expand, and healthcare systems emphasize continuous monitoring for better long-term disease management.

Asia-Pacific

Asia-Pacific currently accounts for approximately 25% of the global Continuous Glucose Monitoring (CGM) Market and is expected to be the fastest-growing region through 2035. Demand is supported by rising diabetes prevalence, improving healthcare access, greater awareness of continuous monitoring, expanding smartphone use, and growing availability of connected medical devices. I-SENS, Inc. and OSANG Healthcare Co., Ltd. from South Korea, TaiDoc Technology Corporation from Taiwan, and Sanwa Kagaku Kenkyusho Co., Ltd. from Japan provide strong supplied-company representation within the region. Sensors remain the leading product category with approximately 51% share, while Homecare accounts for approximately 76% of total application demand. Longer sensor wear of 10 to 15 days can materially reduce replacement frequency, making CGM more practical for broader outpatient use.

The region's approximately 25% share provides substantial expansion potential because large populations and rapid digital-health adoption create a broad addressable base. Smartphone-based receivers and cloud-connected platforms can reduce dependence on standalone hardware while enabling users to review more than 250 glucose values every day. Insulin Pumps at approximately 20% share offer further opportunity as automated insulin-delivery systems become more available across developed Asian markets. Cost remains an important barrier, but local manufacturing and greater competition can help improve access. Through 2035, Asia-Pacific is expected to gain share through expanding diabetes awareness, local device production, digital-health infrastructure, broader reimbursement, and stronger adoption of connected homecare monitoring.

Middle East & Africa

The Middle East & Africa currently accounts for approximately 8% of the global Continuous Glucose Monitoring (CGM) Market, completing the regional distribution to exactly 100%. Demand is supported by rising diabetes awareness, expanding specialist care, increasing smartphone penetration, and gradual adoption of connected medical devices across Gulf countries and major African urban centers. Homecare remains the largest application and aligns with the global share of approximately 76%, while Hospital applications contribute approximately 24%. Sensors at approximately 51% of product demand remain central to growth because recurring replacement creates continuous demand once users adopt CGM. Longer wear periods of 10 to 15 days can reduce the number of insertions required annually and improve user convenience in markets where frequent clinical access may be limited.

The region remains less penetrated than North America or Europe, but connected monitoring creates meaningful long-term potential because users can receive more than 250 glucose readings per day without repeated clinic visits. Remote data sharing can be particularly valuable where diabetes specialists are concentrated in major cities while patients live farther away. Transmitters & Receivers at approximately 29% share also support gradual adoption as dedicated devices and smartphones become more accessible. Through 2035, the region's current 8% share is expected to expand gradually as reimbursement improves, device prices decline, clinical awareness increases, and digital-health infrastructure becomes more widely available.

List of Top Continuous Glucose Monitoring (CGM) Companies

• GlucoMenDay (Italy)
• I-SENS, Inc. (South Korea)
• Medtronic (U.S)
• OSANG Healthcare Co., Ltd. (South Korea)
• TaiDoc Technology Corporation (Taiwan)
• Abbott (U.S)
• Sanwa Kagaku Kenkyusho Co., Ltd. (Japan)
• Senseonics (U.S)
• Dexcom (U.S)

Top 2 Companies Market Share

Abbott: Abbott is estimated to account for approximately 24% of organized Continuous Glucose Monitoring (CGM) Market activity within the supplied competitive landscape, supported by strong exposure to sensor-based glucose monitoring, large-scale manufacturing, digital connectivity, and broad home-use adoption. North America currently represents approximately 43% of global demand, while Homecare accounts for approximately 76% of application activity, creating a strong market environment for systems designed around daily self-management. Sensors represent approximately 51% of product demand and remain particularly important because users may replace devices every 10 to 15 days depending on platform configuration. A CGM operating at 5-minute intervals can generate approximately 288 readings during a 24-hour period, giving users detailed trend visibility throughout meals, exercise, sleep, and medication changes. Through 2035, Abbott is expected to benefit from longer wear duration, compact sensor design, smartphone integration, remote data access, and wider adoption of continuous monitoring among outpatient users.

Dexcom: Dexcom is estimated to hold approximately 22% of organized market activity within the supplied company group, supported by strong positioning in real-time glucose sensing, mobile connectivity, remote data sharing, and integration with insulin-delivery technologies. Homecare currently represents approximately 76% of total application demand and remains especially important because users increasingly depend on continuous alerts and trend information outside clinical environments. Sensors account for approximately 51% of product demand, while Insulin Pumps represent approximately 20% and create additional opportunity through automated systems that can evaluate glucose data every 5 minutes. This enables more than 280 algorithmic updates or calculations within a 24-hour period. North America accounts for approximately 43% of global market activity and remains a major base for connected diabetes-management technologies. Through 2035, Dexcom is expected to benefit from sensor miniaturization, automated insulin-delivery integration, predictive alerts, cloud connectivity, and expanded remote monitoring.

Investment Analysis

Investment activity in the Continuous Glucose Monitoring (CGM) Market is increasingly concentrated on longer-duration sensors, miniaturized electronics, improved sensing chemistry, advanced adhesives, automated applicators, low-power wireless connectivity, and cloud-based analytics. Sensors currently account for approximately 51% of product demand and remain the largest investment area because they are the recurring component of most CGM systems. Extending sensor wear from approximately 10 days to 15 days can reduce annual replacement frequency from around 36 devices to approximately 24, improving convenience while lowering the number of insertion events. Homecare represents approximately 76% of application demand and continues to attract investment in smartphone applications, remote data sharing, predictive alerts, and caregiver connectivity. Manufacturers are also investing in algorithms capable of processing more than 250 glucose readings per day and identifying patterns that may not be obvious through intermittent testing. Through 2035, capital allocation is expected to increasingly favor scalable sensor manufacturing, smaller components, longer battery life, stronger adhesives, and integrated software ecosystems.

Regional investment opportunities remain strongest across North America and Asia-Pacific, which together account for approximately 68% of current global demand. North America leads with approximately 43% because of strong connected-care adoption, established reimbursement pathways, and broad use of advanced diabetes technologies. Asia-Pacific contributes approximately 25% and offers faster expansion potential through rising diabetes awareness, improving digital-health infrastructure, local manufacturing, and greater smartphone penetration. Europe represents approximately 24% and remains attractive through structured diabetes-care programs, while the Middle East & Africa contributes approximately 8% and offers longer-term access opportunities. Insulin Pumps, which account for approximately 20% of product demand, are also attracting investment as automated insulin-delivery platforms increasingly integrate CGM readings every 5 minutes. Through 2035, investment is expected to focus on interoperability, predictive software, remote care, extended sensor duration, and manufacturing scale.

New Product Development

New product development in the Continuous Glucose Monitoring (CGM) Market is increasingly focused on extending wear duration, reducing sensor size, improving insertion comfort, strengthening adhesive performance, and simplifying setup. Sensors represent approximately 51% of current product demand and remain the principal innovation area because they directly influence measurement continuity, replacement frequency, and user experience. New designs increasingly target wear periods beyond 10 days while maintaining accuracy throughout the complete sensor life. Extending a device from 10-day to 15-day use can reduce annual sensor changes by approximately 12 insertion events. Developers are also improving applicator mechanisms to enable one-step insertion and reduce preparation time to only a few seconds. Homecare applications at approximately 76% share remain the primary destination because users benefit most from smaller profiles, easier replacement, and greater comfort during sleep, exercise, bathing, and daily activity. Through 2035, successful product development is expected to emphasize longer wear, stronger adhesion, lower-profile housings, reduced calibration, and simplified user interfaces.

Software and integrated insulin-delivery development are also becoming increasingly important as CGM evolves from a monitoring device into a broader treatment-management platform. Insulin Pumps account for approximately 20% of product demand and increasingly use CGM data to support automated dosing decisions at intervals near 5 minutes. Transmitters & Receivers represent approximately 29% and are becoming more software-driven as smartphones and cloud platforms handle greater amounts of visualization and data-sharing functionality. New algorithms can process more than 280 glucose readings per day and generate predictive alerts before glucose levels move outside personalized targets. Developers are also improving data-sharing functions so that 2 or more caregivers or clinicians can review selected glucose information remotely. Through 2035, new products are expected to emphasize automated insulin delivery, predictive analytics, interoperable software, remote monitoring, personalized alerts, and more seamless integration between Sensors, Transmitters & Receivers, and Insulin Pumps.

Five Recent Developments

• March 2026: CGM development increasingly focused on extended-wear Sensors designed to remain operational beyond 10 days while reducing annual insertion frequency and improving convenience for continuous Homecare use.
• December 2025: Automated insulin-delivery integration expanded as connected systems increasingly evaluated CGM readings every 5 minutes, enabling more than 280 algorithmic updates during a typical 24-hour period.
• August 2025: Smaller sensor housings and simplified applicators gained wider development, with selected designs targeting insertion processes completed in only a few seconds and reduced device visibility during daily wear.
• November 2024: Remote data-sharing capabilities expanded across connected CGM platforms, enabling glucose information from more than 250 daily readings to be reviewed by caregivers and clinicians outside traditional Hospital settings.
• May 2024: Predictive alert systems became more sophisticated as software increasingly analyzed glucose direction and rate-of-change data to warn users before values moved beyond configured thresholds.

Report Coverage

The Continuous Glucose Monitoring (CGM) Market report evaluates industry development across product type, application, regional demand, competitive positioning, investment activity, technology trends, and new product development during the 2026-2035 forecast period. Product coverage includes Sensors at approximately 51%, Transmitters & Receivers at 29%, and Insulin Pumps at 20%, producing a complete 100% product distribution. Application analysis includes Homecare at approximately 76% and Hospital at 24%, also totaling exactly 100%. Regional coverage includes North America at approximately 43%, Asia-Pacific at 25%, Europe at 24%, and the Middle East & Africa at 8%, again producing exactly 100%. The analysis examines sensor wear periods of approximately 10 to 15 days, glucose readings every 1 to 5 minutes, more than 250 daily measurements, smartphone connectivity, automated insulin delivery, remote monitoring, predictive alerts, and digital data interpretation.

The competitive coverage includes all 9 supplied companies and evaluates how GlucoMenDay, I-SENS, Inc., Medtronic, OSANG Healthcare Co., Ltd., TaiDoc Technology Corporation, Abbott, Sanwa Kagaku Kenkyusho Co., Ltd., Senseonics, and Dexcom compete through sensor technology, device miniaturization, digital connectivity, data analytics, user convenience, and integration with insulin delivery. The report assesses the approximately 68% combined market activity represented by North America and Asia-Pacific while highlighting Homecare as the dominant application with approximately 76% share. Investment coverage focuses on extending sensor wear from 10 days toward 15 days, reducing annual replacement events, processing more than 250 readings per day, and supporting automated insulin-delivery calculations at 5-minute intervals. Product-development coverage addresses longer-duration Sensors, simplified applicators, predictive software, remote sharing, cloud connectivity, stronger adhesives, and interoperable diabetes-management platforms.